# Conotoxins from sea snails as potential bone remodeling disruptors

**Authors:** Brenda Iduarte-Frias, Pierrick G J Fournier, Pavel Galindo-Torres, Claudia Ventura-López, Alexei F Licea-Navarro, Johana Bernáldez-Sarabia, Patricia Juárez

PMC · DOI: 10.1093/jbmrpl/ziaf025 · JBMR Plus · 2025-02-10

## TL;DR

This study explores how conotoxins from sea snails affect bone remodeling, showing both potential benefits and risks.

## Contribution

The study identifies specific α-conotoxins that modulate bone remodeling processes in vitro and ex vivo.

## Key findings

- sXm1b and sVc1.1 increased osteoclast activity and decreased osteoblast mineralization.
- sVc1.1 showed higher osteoclast gene modulation and reduced osteoblast gene expression.
- In 3D calvaria models, conotoxins decreased bone area and modulated osteoclast and osteoblast genes.

## Abstract

The ocean provides food and shelter to diverse marine species, and it is an exceptional source of potential bioactive natural products with promising medicinal properties. Among these, α-conotoxins from venom sea snails show tremendous potential. Our study characterized the effects of synthetic α-conotoxins, sXm1b and sVc1.1, on bone remodeling. Transcriptomic analysis showed significant modulation of critical biological processes, leading to increased osteoclast activity and decreased osteoblast mineralization. sXm1b and sVc1.1 treatment also promoted genes involved in osteoblast and osteoclast proliferation. Interestingly, sVC1.1 showed higher osteoclast gene modulation and reduced the expression of genes critical for osteoblast development and differentiation. In vitro, functional evaluations demonstrated increased osteoclastogenesis and resorption, along with decreased differentiation and mineralization by osteoblasts. In a 3D ex vivo calvaria culture model, these conotoxins significantly decreased bone area, increased osteoclast number, and modulated the expression of osteoclast- and osteoblast-related genes. The findings highlight the promise of α-conotoxins as modulators of bone remodeling for treating non-genetic bone mass accumulation problems while also cautioning about potential adverse effects on bone in individuals undergoing conotoxin therapy for pain management.

Graphical Abstract

## Full-text entities

- **Diseases:** bone mass (MESH:D001847), pain (MESH:D010146)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12245161/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12245161/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12245161/full.md

---
Source: https://tomesphere.com/paper/PMC12245161